New drug combinations for advanced bladder cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests adding new treatments to a standard therapy (enfortumab vedotin and pembrolizumab) for people with advanced bladder cancer that hasn't been treated before. It aims to find out if these combinations are safe and work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or spread bladder cancer that can't be removed by surgery.
- You haven't had any previous treatment for advanced bladder cancer (though earlier treatments for early-stage cancer may be okay).
- You must provide a sample of your tumor from a recent biopsy or one stored from a prior procedure.
- You cannot have certain eye conditions like severe dry eye or active cornea problems.
- You must not have serious active heart or blood vessel disease, uncontrolled diabetes, or a history of immune system disease that required treatment in the last 2 years.
- You cannot have active cancer spread to the brain or lining of the brain, or other cancers requiring treatment in the last 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (N-803, pembrolizumab, and enfortumab vedotin) for advanced bladder cancer that has not been treated with systemic therapy. The goal is to see if this combination can shrink or control the cancer and improve outcomes.
This trial tests a new targeted drug, BL-M07D1, against standard chemotherapy in people with advanced bladder cancer that has grown after immunotherapy. It may offer a new treatment option for those with a specific protein (HER2) on their cancer cells.
This Phase 2 study tests how well pembrolizumab and an antibody-drug medicine (EV) given with bladder radiation work for non-metastatic bladder cancer that is mostly urothelial. It may help some people control the cancer without it spreading to other organs.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial adds an investigational drug, GB-4362, to a standard combination of two medicines (enfortumab vedotin and pembrolizumab) for advanced bladder cancer. The study wants to see if adding this drug is safe and helps treat the cancer better.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) given before surgery to shrink or eliminate bladder or upper tract cancer. The goal is to see if this approach reduces the chance of cancer coming back and improves outcomes.
Hear when a new Bladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.